Istituto di Biostrutture e Bioimmagini-CNR, via Mezzocannone 16, 80134 Naples, Italy
Università degli Studi di Firenze, Laboratorio di Chimica Bioinorganica, Via della Lastruccia 3, I-50019 Sesto Fiorentino (Firenze), Italy
Universit degli Studi di Firenze, Laboratorio di Chimica Bioinorganica, Via della Lastruccia 3, I-50019 Sesto Fiorentino (Firenze), Italy
References: Friedman, J.M., A war on obesity, not the obese (2003) Science, 299, pp. 856-85
Hill, J.O., Wyatt, H.R., Reed, G.W., Peters, J.C., Obesity and the environment: Where do we go from here? (2003) Science, 299, pp. 853-855
Ioannides-Demos, L.L., Proietto, J., Tonkin, A.M., McNeil, J.J., Safety of drug therapies used for weight loss and treatment of obesity (2006) Drug Saf, 29, pp. 277-302
Campfield, L.A., Smith, F.J., Burn, P., Strategies and potential molecular targets for obesity treatment (1998) Science, 280, pp. 1383-1387
http://www.iotf.org, International Obesity Task Force. Available from:, Last accessed 3 March 2008Ethan, M., Berke, M.D., Nancy, E., Morden, M.D., Medical management of obesity (2000) Am Fam Physician, 62, pp. 419-426
Lyznicki, J.M., Young, D.C., Riggs, J.A., Davis, R.M., Obesity: Assessment and management in primary care (2001) Am Fam Physician, 63, pp. 2185-2196
Despres, J.P., Lemieux, S., Lamarche, B., The insulin resistance-dyslipidemic syndrome: Contribution of visceral obesity and therapeutic implications (1995) Int J Obes Relat Metab Disord, 19 (SUPPL. L), pp. S76-S86
Van Gaal, L., Mertens, I., Effects of obesity on cardiovascular systems and blood pressure control, digestive disease and cancer (1998) Clinical obesity, pp. 205-225. , Kopelman P, editor, Oxford: Blackwell
Avenell, A., Broom, J., Brown, T.J., Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement (2004) Health Technol Assess, 8, pp. 1-182
Chaput, J.P., Tremblay, A., Current and novel approaches to the drug therapy of obesity (2006) Eur J Clin Pharmacol, 62, pp. 793-803
Cheetham, S.C., Jackson, H.C., Vickers, S.P., Novel targets for the treatment of obesity: A review of progress (2004) Drug Discov Today Ther Strateg, 1, pp. 227-235
Bays, H., Dujovne, C., Pharmacotherapy of obesity: Currently marketed and upcoming agents (2002) Am J Cardiovasc Drugs, 2, pp. 245-253
Weintraub, M., Long-term weight control study: Conclusions (1992) Clin Pharmacol Ther, 51, pp. 642-646
Connolly, H.M., Crary, J.L., McGoon, M.D., Valvular heart disease associated with fenfluraminephentermine (1997) N Engl J Med, 337, pp. 581-588
McNelly, W., Goa, K.L., Sibutramine. A review of its contribution to the management of obesity (1998) Drugs, 56, pp. 1093-1124
Uscombe, G.P., Hopcroft, R.H., Thomas, P.C., Buckett, W.R., The contribution of metabolites to the rapid and potent down regulation of rat cortical beta adrenoreceptors by the putative antidepressant sibutramine hydrochloride (1989) Neuropharmacology, 28, pp. 129-134
Bray, G.A., Blackburn, G.L., Ferguson, J.M., Sibutramine produces dose-related weight loss (1999) Obes Res, 7, pp. 189-198
James, W.P., Astrup, A., Finer, N., Effect of sibutramine on weight maintenance after weight loss: A randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance (2000) Lancet, 356, pp. 2119-2125
Padwal, R.S., Majumdar, S.R., Drug treatments for obesity: Orlistat, sibutramine, and rimonabant (2007) Lancet, 369, pp. 71-77
Sidhaye, A., Cheskin, L.J., Pharmacologic treatment of obesity (2006) Adv Psychosom Med, 27, pp. 42-52
Davidson, M.H., Hauptman, J., DiGirolamo, M., Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat (1999) JAMA, 281, pp. 235-242
Hollander, P.A., Elbein, S.C., Hirsch, I.B., Role of orlistat in the treatment of obese patients with type 2 diabetes (1998) Diabetes Care, 21, pp. 1288-1294
Sjöström, L., Rissanen, A., Andersen, T., Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group (1998) Lancet, 352, pp. 167-172
Heymsfield, S.B., Segal, K.R., Hauptman, J., Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults (2000) Arch Intern Med, 160, pp. 1321-1326
Kelley, D.E., Bray, G.A., Pi-Sunyer, F.X., Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1 year randomized controlled trial (2002) Diabetes Care, 25, pp. 1033-1041
Lindgärde, F., The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study (2000) J Intern Med, 248, pp. 245-254
Rössner, S., Sjöström, L., Noack, R., Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group (2000) Obes Res, 8, pp. 49-61
Gadde, K.M., Endocannabinoid receptor antagonists and other emerging pharmacological strategies for weight reduction (2005) Curr Drug Targets Cardiovasc Haematol Disord, 5, pp. 549-556
Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial (2006) JAMA, 295, pp. 761-775. , for the RIO-North America Study Group
Bray, G.A., Ryan, D.H., Drug treatment of the overweight patient (2007) Gastroeneterology, 132, pp. 2239-2252
Rucker, D., Padwall, R., LI, S.K., Long term pharmacotherapy for obesity and overweight: Updated meta-analysis (2007) BMJ, 335, pp. 1194-1199
Bays, H.E., Current and investigational antiobesity agents and obesity therapeutic treatment targets (2004) Obes Res, 12, pp. 1197-1211
Obici, S., Feng, Z., Arduini, A., Inhibition of hypothalamic carnitine palmitoyltransferase-1 decreases food intake and glucose production (2003) Nat Med, 9, pp. 756-761
Supuran, C.T., Scozzafava, A., Casini, A., Carbonic anhydrase inhibitors (2003) Med Res Rev, 23, pp. 146-189
Supuran, C.T., Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity (2003) Expert Opin Ther Patents, 13, pp. 1545-1550
Tripp, B.C., Smith, K., Ferry, J.G., Carbonic anhydrase: New insights for an ancient enzyme (2001) J Biol Chem, 276, pp. 48615-48618
(2004) Carbonic anhydrase: Its inhibitors and activators, , Supuran CT, Scozzafava A, Conway J, editors, Boca Raton, FL: CRC Press
Dodgson, S.J., Inhibition of mitochondrial carbonic anhydrase: A discrepancy examined (1987) J Appl Physiol, 63, pp. 2134-2141
Dodgson, S.J., Cherian, K., Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis (1989) Am J Physiol, 257, pp. E791-E796
Spencer, I.M., Hargreaves, I., Chegwidden, W.R., Effect of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust (1988) Biochem Soc Trans, 16, pp. 973-974
Chegwidden, W.R., Spencer, I.M., Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus (1996) Comp Biochem Physiol, 115 B, pp. 247-254
Chegwidden, W.R., Dodgson, S.J., Spencer, I.M., The roles of carbonic anhydrase in metabolism, cell growth and cancer in animals (2000) The carbonic anhydrases, pp. 343-363. , Chegwidden WR, Edwards Y, Carter N, editors, new horizons. Birkhäuser, Basel
Lynch, C.J., Fox, H., Hazen, S.A., Role of hepatic carbonic anhydrase in de novo lipogenesis (1995) Biochem J, 310, pp. 197-202
Hazen, S.A., Waheed, A., Sly, W.S., Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes (1996) FASEB J, 10, pp. 481-490
Atwood, P.V., The structure and mechanism of action of pyruvate carboxylase (1995) Int J Biochem Cell Biol, 27, pp. 231-249
Alldred, J.B., Reilly, K.E., Short-term regulation of acetyl CoA carboxylase in tissues of higher animals (1997) Prog Lipid Res, 35, pp. 371-385
Forster, R.E., Dodgson, S.J., Membrane transport and provision of substrates for carbonic anhydrase in vertebrates (2000) The carbonic anhydrases, pp. 263-280. , Chegwidden WR, Edwards Y, Carter N, editors, new horizons. Birkhäuser Verlag, Basel
Parkkila, S., An overview of the distribution and function of carbonic anhydrase isozymes in mammals (2000) The carbonic anhydrases, pp. 79-94. , Chegwidden WR, Edwards Y, Carter N, editors, new horizons, Birkhäuser Verlag, Basel
Parkkila, S., Parkkila, A.K., Kivelä, J., Role of carbonic anhydrase and its inhibitors in biological science related to gastroenterology, neurology and nephrology (2000) The carbonic anhydrases, pp. 283-301. , Chegwidden WR, Edwards Y, Carter N, editors, new horizons. Birkhäuser, Basel
Maren, T.H., Role of carbonic anhydrase in aqueous humor and cerebrospinal fluid formation (1992) Barriers and fluids of the eye and brain, pp. 37-48. , Segal MB, editor, London: MacMillan Press
Maren, T.H., The development of topical carbonic anhydrase inhibitors (1995) J Glaucoma, 4, pp. 49-62
Maren, T.H., Carbonic anhydrase: Chemistry, physiology and inhibition (1967) Physiol Rev, 47, pp. 595-781
Shank, R.P., Gardocki, J.F., Vaught, J.L., Topiramate: Preclinical evaluation of structurally novel anticonvulsant (1994) Epilepsia, 35, pp. 450-460
Edmonds, H.L., Jiang, Y.D., Zhang, P.Y., Shank, R.P., Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy (1996) Life Sci, 59, pp. PL127-PL131
Stringer, J.L., A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat (2000) Epilepsy Res, 40, pp. 147-153
Sabers, A., Gram, L., Newer anticonvulsants: Comparative review of drug interactions and adverse effects (2000) Drugs, 60, pp. 23-33
Bourgeois, B.F.D., Pharmacokinetics and pharmacodynamics of topiramate (2000) J Child Neurol, 15, pp. S27-S30
Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: summary of the Fifth Eilat Conference. Epilepsy Res 2001
43:11-58Gordon, A., Price, L.H., Mood stabilization and weight loss with topiramate (1999) Am J Psychiatry, 156, pp. 968-969
Picard, F., Deshaies, Y., Lalonde, J., Topiramate reduces energy and fat gains in lean (Fa/?) and obese (fa/fa) Zucker rats (2000) Obes Res, 8, pp. 656-663
Mancini, M.C., Halpern, A., Investigational therapies in the treatment of obesity (2006) Expert Opin Investig Drugs, 15, pp. 897-915
Casini, A., Antel, J., Abbate, F., Carbonic anhydrase inhibitors: SAR and X-ray crystallographic study for the interaction of sugar sulfamates/sulfamides with isozymes I, II and IV (2003) Bioorg Med Chem Lett, 13, pp. 841-845
Chen, R.F., Kernohan, J.C., Combination of bovine carbonic anhydrase with a fluorescent sulfonamide (1967) J Biol Chem, 242, pp. 5813-5823
Vitale, R.M., Pedone, C., Amodeo, P., Carbonic anhydrase inhibitors: Molecular modeling study for the interaction of zonisamide and topiramate with isozyme va (2007) Bioorg Med Chem, 15, pp. 4152-4158
Zareba, G., Zonisamide: Review of its use in epilepsy therapy (2005) Drug Today (Barc), 41, pp. 589-597
Canitano, R., Clinical experience with topiramate to counteract neuroleptic induced weight gain in 10 individuals with autistic spectrum disorders (2005) Brain Dev, 27, pp. 228-232
Kim, C.S., Zonisamide effective for weight loss in women (2003) J Fam Pract, 52, pp. 600-601
Gadde, K.M., Franciscy, D.M., Wagner 2nd, H.R., Krishnan, K.R., Zonisamide for weight loss in obese adults: A randomized controlled trial (2003) JAMA, 289, pp. 1820-1825
De Simone, G., Di Fiore, A., Menchise, V., Carbonic anhydrase inhibitors. Zonisamide is an effective inhibitor of the cytosolic isozyme II and mitochondrial isozyme V: Solution and X-ray crystallographic studies (2005) Bioorg Med Chem Lett, 15, pp. 2315-2320
Masuda, Y., Karasawa, T., Inhibitory effect of zonisamide on human carbonic anhydrase in vitro (1993) Arzneimittelforschung, 43, pp. 416-418
Friedman, J. M., A war on obesity, not the obese (2003) Science, 299, pp. 856-85
Hill, J. O., Wyatt, H. R., Reed, G. W., Peters, J. C., Obesity and the environment: Where do we go from here? (2003) Science, 299, pp. 853-855
Campfield, L. A., Smith, F. J., Burn, P., Strategies and potential molecular targets for obesity treatment (1998) Science, 280, pp. 1383-1387
http: //www. iotf. org, International Obesity Task Force. Available from:, Last accessed 3 March 2008Ethan, M., Berke, M. D., Nancy, E., Morden, M. D., Medical management of obesity (2000) Am Fam Physician, 62, pp. 419-426
Lyznicki, J. M., Young, D. C., Riggs, J. A., Davis, R. M., Obesity: Assessment and management in primary care (2001) Am Fam Physician, 63, pp. 2185-2196
Despres, J. P., Lemieux, S., Lamarche, B., The insulin resistance-dyslipidemic syndrome: Contribution of visceral obesity and therapeutic implications (1995) Int J Obes Relat Metab Disord, 19 (SUPPL. L), pp. S76-S86
Chaput, J. P., Tremblay, A., Current and novel approaches to the drug therapy of obesity (2006) Eur J Clin Pharmacol, 62, pp. 793-803
Cheetham, S. C., Jackson, H. C., Vickers, S. P., Novel targets for the treatment of obesity: A review of progress (2004) Drug Discov Today Ther Strateg, 1, pp. 227-235
Connolly, H. M., Crary, J. L., McGoon, M. D., Valvular heart disease associated with fenfluraminephentermine (1997) N Engl J Med, 337, pp. 581-588
Uscombe, G. P., Hopcroft, R. H., Thomas, P. C., Buckett, W. R., The contribution of metabolites to the rapid and potent down regulation of rat cortical beta adrenoreceptors by the putative antidepressant sibutramine hydrochloride (1989) Neuropharmacology, 28, pp. 129-134
Bray, G. A., Blackburn, G. L., Ferguson, J. M., Sibutramine produces dose-related weight loss (1999) Obes Res, 7, pp. 189-198
James, W. P., Astrup, A., Finer, N., Effect of sibutramine on weight maintenance after weight loss: A randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance (2000) Lancet, 356, pp. 2119-2125
Padwal, R. S., Majumdar, S. R., Drug treatments for obesity: Orlistat, sibutramine, and rimonabant (2007) Lancet, 369, pp. 71-77
Davidson, M. H., Hauptman, J., DiGirolamo, M., Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat (1999) JAMA, 281, pp. 235-242
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Role of orlistat in the treatment of obese patients with type 2 diabetes (1998) Diabetes Care, 21, pp. 1288-1294
Sj str m, L., Rissanen, A., Andersen, T., Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group (1998) Lancet, 352, pp. 167-172
Heymsfield, S. B., Segal, K. R., Hauptman, J., Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults (2000) Arch Intern Med, 160, pp. 1321-1326
Kelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1 year randomized controlled trial (2002) Diabetes Care, 25, pp. 1033-1041
Lindg rde, F., The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study (2000) J Intern Med, 248, pp. 245-254
R ssner, S., Sj str m, L., Noack, R., Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group (2000) Obes Res, 8, pp. 49-61
Gadde, K. M., Endocannabinoid receptor antagonists and other emerging pharmacological strategies for weight reduction (2005) Curr Drug Targets Cardiovasc Haematol Disord, 5, pp. 549-556
Pi-Sunyer, F. X., Aronne, L. J., Heshmati, H. M., Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial (2006) JAMA, 295, pp. 761-775. , for the RIO-North America Study Group
Bray, G. A., Ryan, D. H., Drug treatment of the overweight patient (2007) Gastroeneterology, 132, pp. 2239-2252
Bays, H. E., Current and investigational antiobesity agents and obesity therapeutic treatment targets (2004) Obes Res, 12, pp. 1197-1211
Supuran, C. T., Scozzafava, A., Casini, A., Carbonic anhydrase inhibitors (2003) Med Res Rev, 23, pp. 146-189
Supuran, C. T., Carbonic anhydrase inhibitors in the treatment and prophylaxis of obesity (2003) Expert Opin Ther Patents, 13, pp. 1545-1550
Tripp, B. C., Smith, K., Ferry, J. G., Carbonic anhydrase: New insights for an ancient enzyme (2001) J Biol Chem, 276, pp. 48615-48618
(2004) Carbonic anhydrase: Its inhibitors and activators, , Supuran CT, Scozzafava A, Conway J, editors, Boca Raton, FL: CRC Press
Dodgson, S. J., Inhibition of mitochondrial carbonic anhydrase: A discrepancy examined (1987) J Appl Physiol, 63, pp. 2134-2141
Dodgson, S. J., Cherian, K., Mitochondrial carbonic anhydrase is involved in rat renal glucose synthesis (1989) Am J Physiol, 257, pp. E791-E796
Spencer, I. M., Hargreaves, I., Chegwidden, W. R., Effect of the carbonic anhydrase inhibitor acetazolamide on lipid synthesis in the locust (1988) Biochem Soc Trans, 16, pp. 973-974
Chegwidden, W. R., Spencer, I. M., Carbonic anhydrase provides bicarbonate for de novo lipogenesis in the locus (1996) Comp Biochem Physiol, 115 B, pp. 247-254
Lynch, C. J., Fox, H., Hazen, S. A., Role of hepatic carbonic anhydrase in de novo lipogenesis (1995) Biochem J, 310, pp. 197-202
Hazen, S. A., Waheed, A., Sly, W. S., Differentiation-dependent expression of CA V and the role of carbonic anhydrase isozymes in pyruvate carboxylation in adipocytes (1996) FASEB J, 10, pp. 481-490
Atwood, P. V., The structure and mechanism of action of pyruvate carboxylase (1995) Int J Biochem Cell Biol, 27, pp. 231-249
Alldred, J. B., Reilly, K. E., Short-term regulation of acetyl CoA carboxylase in tissues of higher animals (1997) Prog Lipid Res, 35, pp. 371-385
Forster, R. E., Dodgson, S. J., Membrane transport and provision of substrates for carbonic anhydrase in vertebrates (2000) The carbonic anhydrases, pp. 263-280. , Chegwidden WR, Edwards Y, Carter N, editors, new horizons. Birkh user Verlag, Basel
Bartlett, J. D., Jaanus, S. D., (1989) Clinical ocular pharmacology, , Boston, MA: Butterworth
Maren, T. H., Role of carbonic anhydrase in aqueous humor and cerebrospinal fluid formation (1992) Barriers and fluids of the eye and brain, pp. 37-48. , Segal MB, editor, London: MacMillan Press
Maren, T. H., The development of topical carbonic anhydrase inhibitors (1995) J Glaucoma, 4, pp. 49-62
Maren, T. H., Carbonic anhydrase: Chemistry, physiology and inhibition (1967) Physiol Rev, 47, pp. 595-781
Shank, R. P., Gardocki, J. F., Vaught, J. L., Topiramate: Preclinical evaluation of structurally novel anticonvulsant (1994) Epilepsia, 35, pp. 450-460
Edmonds, H. L., Jiang, Y. D., Zhang, P. Y., Shank, R. P., Anticonvulsant activity of topiramate and phenytoin in a rat model of ischemia-induced epilepsy (1996) Life Sci, 59, pp. PL127-PL131
Stringer, J. L., A comparison of topiramate and acetazolamide on seizure duration and paired-pulse inhibition in the dentate gyrus of the rat (2000) Epilepsy Res, 40, pp. 147-153
Bourgeois, B. F. D., Pharmacokinetics and pharmacodynamics of topiramate (2000) J Child Neurol, 15, pp. S27-S30
43: 11-58Gordon, A., Price, L. H., Mood stabilization and weight loss with topiramate (1999) Am J Psychiatry, 156, pp. 968-969
Mancini, M. C., Halpern, A., Investigational therapies in the treatment of obesity (2006) Expert Opin Investig Drugs, 15, pp. 897-915
Chen, R. F., Kernohan, J. C., Combination of bovine carbonic anhydrase with a fluorescent sulfonamide (1967) J Biol Chem, 242, pp. 5813-5823
Vitale, R. M., Pedone, C., Amodeo, P., Carbonic anhydrase inhibitors: Molecular modeling study for the interaction of zonisamide and topiramate with isozyme va (2007) Bioorg Med Chem, 15, pp. 4152-4158
Kim, C. S., Zonisamide effective for weight loss in women (2003) J Fam Pract, 52, pp. 600-601
Gadde, K. M., Franciscy, D. M., Wagner 2nd, H. R., Krishnan, K. R., Zonisamide for weight loss in obese adults: A randomized controlled trial (2003) JAMA, 289, pp. 1820-1825
Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity